TGFA and neoplasm: The other category comprises anti-EGFR monoclonal antibodies, which mainly act on the extracellular domain of EGFR, competitively inhibiting the binding of various ligands (such as EGF and TGF-α) to the receptor and blocking its phosphorylation, which finally leads to the loss of EGFR activity, inhibition of tumor growth, and induction of apoptosis.